David Hollander is CMO & Global Therapeutics Lead of Revance Therapeutics, Inc.. Currently has a direct ownership of 0 shares of RVNC, which is worth approximately $0. The most recent transaction as insider was on Feb 06, 2025, when has been sold 95,212 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
n/a 3M change
n/a 12M change
Total Value Held $0

David Hollander Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 06 2025
SELL
Sale (or disposition) back to the issuer
-
95,212 Reduced 100.0%
0 Common Stock
Feb 04 2025
SELL
Disposition due to a tender of shares in a change of control transaction
$35,525 $3.65 p/Share
9,733 Reduced 9.27%
95,212 Common Stock
Nov 18 2024
SELL
Open market or private sale
$16,296 $4.17 p/Share
3,908 Reduced 3.59%
104,945 Common Stock

Also insider at

AERI
AERIE PHARMACEUTICALS INC Healthcare
KPRX
KIORA PHARMACEUTICALS INC Healthcare
DH

David Hollander

CMO & Global Therapeutics Lead
Durham, NC

Track Institutional and Insider Activities on RVNC

Follow Revance Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RVNC shares.

Notify only if

Insider Trading

Get notified when an Revance Therapeutics, Inc. insider buys or sells RVNC shares.

Notify only if

News

Receive news related to Revance Therapeutics, Inc.

Track Activities on RVNC